Incidence of acquired pure red cell aplasia: a nationwide epidemiologic analysis with 2 registry databases in Japan.
Journal
Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425
Informations de publication
Date de publication:
27 12 2022
27 12 2022
Historique:
accepted:
23
04
2022
received:
03
11
2021
pubmed:
7
5
2022
medline:
30
12
2022
entrez:
6
5
2022
Statut:
ppublish
Résumé
Acquired pure red cell aplasia (PRCA) is a rare syndrome characterized by anemia with reticulocytopenia and a marked reduction in erythroid precursors. Given its rarity, the true incidence is largely unknown, and epidemiological data representing the general population, with a description of the full spectrum of etiologies, are scarce. An epidemiological study on PRCA in Japan conducted 30 years ago estimated the annual incidence as 0.3 per million. To update the data and investigate the incidence and demographics of PRCA, we conducted a nationwide epidemiological study using the Japanese Society of Hematology (JSH) Hematologic Disease Registry, a hematologic disease registration database managed by the JSH and the Diagnosis Procedure Combination (DPC) study data available at a website of the Ministry of Health, Labor, and Welfare (MHLW) of Japan. A total of 1055 patients with newly diagnosed acquired PRCA were identified between 2012 and 2019, and the average annual incidence was calculated at 1.06 (95% confidence interval [CI], 0.83-1.28) per million. The median age was 73 (range, 18-99) years. The female-to-male ratio was 1.5:1, and the female predominance was most prominent in the child-bearing age group. Sixty-nine percent of acquired PRCA was idiopathic. The incidence of PRCA was approximately 20% of that of aplastic anemia (AA) during the same period. Approximately 0.98 patients per million per year (95% CI, 0.89-1.07) required hospitalization for the treatment of PRCA. These results are expected to contribute to the discussion of resource allocation for PRCA in the aging population in many countries, including Japan.
Identifiants
pubmed: 35522950
pii: 485186
doi: 10.1182/bloodadvances.2021006486
pmc: PMC9806328
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
6282-6290Informations de copyright
© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.
Références
Ann Hematol. 2010 Apr;89(4):331-9
pubmed: 20084380
Cancer. 1989 Nov 1;64(9):1872-8
pubmed: 2507126
Nephrol Dial Transplant. 2015 Mar;30(3):451-60
pubmed: 25239637
Arthritis Rheum. 2007 Apr;56(4):1251-62
pubmed: 17393454
Eur J Haematol. 2001 Sep;67(3):152-7
pubmed: 11737247
Eur J Cardiothorac Surg. 2021 Apr 13;59(3):641-649
pubmed: 33188679
Ann Thorac Surg. 1991 Jan;51(1):152-6
pubmed: 1985561
Blood. 2021 Apr 15;137(15):2001-2009
pubmed: 33657207
Br J Haematol. 2015 Jun;169(6):879-86
pubmed: 25807974
Br J Haematol. 2018 Nov;183(3):421-427
pubmed: 30117139
Br J Haematol. 2013 Mar;160(6):798-805
pubmed: 23330820
Curr Opin Rheumatol. 1999 Sep;11(5):352-6
pubmed: 10503654
Eur J Haematol. 2009 Apr;82(4):308-14
pubmed: 19220421
Hematology. 2008 Apr;13(2):88-91
pubmed: 18616874
Transfusion. 2008 Aug;48(8):1754-62
pubmed: 18482185
Int J Hematol. 2017 Oct;106(4):500-507
pubmed: 28664500
Blood. 2015 Jul 23;126(4):463-70
pubmed: 26065656
Haematologica. 2007 Aug;92(8):1021-8
pubmed: 17640861
Immunol Lett. 2010 Sep 6;133(1):6-13
pubmed: 20637236
Bone Marrow Transplant. 2013 Mar;48(3):452-8
pubmed: 23208313
Oncotarget. 2016 Sep 20;7(38):61419-61425
pubmed: 27542218
Blood Adv. 2018 Oct 23;2(20):2704-2712
pubmed: 30337298
Tanaffos. 2019 Apr;18(4):355-364
pubmed: 32607118
Haematologica. 2018 Feb;103(2):221-230
pubmed: 29217782
Br J Haematol. 2021 May;193(4):814-826
pubmed: 33844842
Blood. 1984 Feb;63(2):277-86
pubmed: 6581839